Fitch Ratings upgraded its credit grade on both Bausch + Lomb Corp. and its parent company Bausch Health Cos., but said the eye care unit’s ratings will continue to be under pressure unless the two ...

Bausch Health Companies (BHC) and its gastroenterology business, Salix Pharmaceuticals, announced the U.S. District Court for the District of ...

Bausch + Lomb issued the recall after the company received reports of toxic anterior segment syndrome, or an inflammatory ...

Bausch Health's Aplenzin could revolutionize TRD care, addressing a $3B market opportunity while aiding BHC stock's financial ...

The eye health company Bausch + Lomb announced on Monday that it is recalling several of its intraocular lenses due to safety ...

Bausch + Lomb, a leading global eye health company, announced a voluntary recall of its Envista Aspire, Envista Envy and ...

NEW YORK CITY, NY / ACCESS Newswire / April 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst ...

Bausch + Lomb is recalling intraocular lenses (IOLs) on its enVista platform. This action was taken after the company ...

Fitch Ratings has upgraded the Issuer Default Rating (IDR) of Bausch + Lomb Corporation (BLCO) to ’B’ from ’B-’ on April 17, 2025. The rating on its senior secured debt was also raised to ’BB’ with a ...

Investing.com -- Bausch Health Companies Inc (NYSE: BHC) stock closed up 13.3% following a favorable court decision. The U.S. District Court for the District of Columbia ruled in favor of the company ...